ASLAN Pharmaceuticals Ltd - ADR

Aslan Pharmaceuticals Ltd. is a clinical-stage immunology biopharmaceutical company, which engages in the development of novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes ASLAN003 and Eblasakimab. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ASLAN is a pharmaceutical company that develops novel medicines for global markets. It specializes in clinical-stage immunology and oncology-focused biopharmaceuticals.

MENLO PARK, Calif. and SINGAPORE, Sept. 02, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to give an in-person company presentation at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022, at 10:30 am ET. The conference will be held from September 12 to 14, 2022, virtually and in-person at the Lotte New York Palace Hotel.

ASLAN Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

MENLO PARK, Calif. and SINGAPORE and CAMBRIDGE, Mass.

ASLAN PHARMACEUTICALS SIGNS LICENSE AGREEMENT WITH BELLE.AI TO USE BELLESTUDY™ IMAGE CAPTURE SOFTWARE IN ATOPIC DERMATITIS CLINICAL TRIALS

MENLO PARK, Calif. and CAMBRIDGE, Mass. and SINGAPORE, Aug. 25, 2022 (GLOBE NEWSWIRE) -- BelleTorus Corporation (“Belle.ai”) and ASLAN Pharmaceuticals (Nasdaq: ASLN), today announced that ASLAN has licensed belleStudy™ digital image capture software in support of ASLAN's clinical trials for atopic dermatitis (AD) across several global sites. ASLAN will make the image capture software component of belleStudy™ available to all investigators of TREK-AD, its ongoing global phase 2b trial of eblasakimab, expected to generate topline data in the first half of 2023.

ASLAN Pharmaceuticals Signs License Agreement With Belle.ai to Use belleStudy™ Image Capture Software in Atopic Dermatitis Clinical Trials

MENLO PARK, Calif. and SINGAPORE, Aug. 22, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will be hosting a R&D Day on Thursday, September 15, 2022, from 10:00am to 1:30pm ET at the St. Regis Hotel in New York, NY.

ASLAN Pharmaceuticals to Host a Hybrid R&D Day on September 15, 2022

- Company maintains healthy operating position with US$78.1 million in cash, cash equivalents and short-term investments as of June 30, 2022, runway through late 2023-  Three abstracts showcasing new findings related to eblasakimab have been accepted as e-posters at the 31 st European Academy of Dermatology and Venereology (EADV) Annual Congress, from September 7 to 10, 2022, in Milan, Italy-  The Phase 2b TREK-AD trial for eblasakimab in moderate-to-severe AD is on track to generate topline data in the first half of 2023-  Company to host R&D Day; details will follow closer to the date of September 15, 2022

ASLAN Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

MENLO PARK, Calif. and SINGAPORE, June 07, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has initiated a research collaboration with Dr Shawn Kwatra, as an advisor, from Johns Hopkins University School of Medicine and Dr Madan Kwatra from Duke University Medical Center to investigate the unique role of the IL-13Ra1 subunit, distinct from the role of other pathway components, in Type 2-mediated inflammatory diseases, specifically atopic dermatitis (AD).

ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling in Atopic Dermatitis

MENLO PARK, Calif. and SINGAPORE, May 31, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will participate in a fireside chat at the Jefferies Global Healthcare Conference. The conference will be held in-person in New York, NY, June 8 - 10, 2022.

ASLAN Pharmaceuticals to Participate in Fireside Chat at Jefferies Global Healthcare Conference

MENLO PARK, Calif. and SINGAPORE, May 20, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the presentation of a poster highlighting new data and insights related to neuronal itch mechanisms through eblasakimab's targeting of IL-13Rα1 at the Society for Investigative Dermatology (SID) Annual Meeting. The data were presented by Ferda Cevikbas PhD, Head of Translational Sciences at ASLAN.

ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting

MENLO PARK, Calif. and SINGAPORE, April 27, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2022, and provided an update on recent corporate activities.

ASLAN Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

MENLO PARK, Calif. and SINGAPORE, April 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present at the 21st Annual Needham Virtual Healthcare Conference. The conference will be held virtually from April 11 to 14, 2022.

ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022

MENLO PARK, Calif. and SINGAPORE, March 28, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the oral presentation of data from the completed Phase 1b multiple-ascending-dose (MAD) study that established proof of concept for eblasakimab (ASLAN004) in moderate-to-severe atopic dermatitis (AD) during the late-breaking research session at the 2022 American Academy of Dermatology (AAD) Annual Meeting on March 26, 2022, in Boston, Massachusetts. The data were presented by Dr Andrew Blauvelt, President, Oregon Medical Research Center.

ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting

MENLO PARK, Calif. and SINGAPORE, March 25, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2021, and provided an update on recent corporate activities.

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

- Topline data from the eblasakimab Phase 1b multiple-ascending-dose study will be presented during the “Late-breaking Research: Clinical Trials” session at the 2022 American Academy of Dermatology Annual Meeting on March 26

ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic Dermatitis for Oral Presentation at the 2022 American Academy of Dermatology Annual Meeting

ASLAN (ASLN) screens the first patient in the phase II dose ranging study evaluating its investigational monoclonal antibody in patients with atopic dermatitis.

ASLAN (ASLN) Starts Phase IIb Study in Atopic Dermatitis

ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has screened the first patient in its Phase 2b dose-ranging study of eblasakimab (ASLAN004) in adults with moderate-to-severe atopic dermatitis (AD).  Eblasakimab is a monoclonal antibody targeting the IL-13 receptor.

ASLAN Pharma Kickstarts Mid-Stage Atopic Dermatitis Trial, Data Expected In 2023

MENLO PARK, Calif. and SINGAPORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has screened the first patient in its Phase 2b dose-ranging clinical study of eblasakimab in adults with moderate-to-severe atopic dermatitis (AD). Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to provide a differentiated treatment option for patients. ASLAN expects to report topline findings from the 16-week treatment period in the first half of 2023.

ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis

-  Management to host the second webinar in ASLAN's A 4 series on Thursday, January 20, 2022, at 12:00pm ET

ASLAN Pharmaceuticals to Host New Episode in A4 KOL Series: Aspects of Atopic Dermatitis and ASLAN004

MENLO PARK, Calif. and SINGAPORE., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright Bioconnect Conference on January 10, 2022. The conference will be held virtually from January 10 to January 13, 2022.

ASLAN Pharmaceuticals to Present at H.C. Wainwright Bioconnect Conference 2022

MENLO PARK, Calif. and SINGAPORE, Oct. 26, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2021, and provided an update on recent corporate activities.

ASLAN Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

MENLO PARK, Calif. and SINGAPORE, Oct. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced a collaboration with renowned inflammatory skin disease expert Dr Emma Guttman-Yassky, MD PhD, to conduct research that will continue throughout ASLAN's Phase 2b program to identify and characterize the effects of ASLAN004 on disease-associated skin and serum-biomarkers in adults with moderate-to-severe atopic dermatitis (AD).

ASLAN Pharmaceuticals Announces Scientific Collaboration With Dr Emma Guttman-Yassky on Identification of ASLAN004-Specific Biomarkers

- Management to host the first in a series of KOL webinars beginning Monday, October 25, 2021, at 10:00am ET

ASLAN Pharmaceuticals Announces KOL Event Series to Discuss Atopic Dermatitis Treatment Landscape and ASLAN004

MENLO PARK, Calif. and SINGAPORE, Oct. 14, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointments of Dr Melinda Jennifer Gooderham, MSc MD FRCPC, Dr Jacob Thyssen, MD PhD DmSci, and Associate Professor Peter Foley, BMedSci MBBS MD FACD, as members of its Scientific Advisory Board (SAB).

ASLAN Pharmaceuticals Announces Expansion of Scientific Advisory Board With Appointment of Leading Global Experts in Dermatology and Immunology

The stock price of Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) fell by over 25%. This is why it happened.

ASLN Stock: Why It Fell Over 25% Today

ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has announced topline data from its Phase 1 study of ASLAN004 for moderate-to-severe atopic dermatitis (AD).  In March 2021, ASLAN announced interim data from three dose-escalation cohorts (200mg, 400mg, and 600mg).

Why Did ASLAN Pharma Shares Plunge Despite Positive Atopic Dermatitis Trial Data?

- Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile

News for ASLAN Pharmaceuticals Ltd - ADR Stock (ASLN)